Alligator Bioscience Ab · OMXSTO:ATORX
Alligator Bioscience Ab — DNB SME Conference April 2017
22 slides from Alligator Bioscience Ab's conference presentation, April 2017
Slide 1: Company Presentation – DNB SME Conference, April 2017
COMPANY PRESENTATION DNB SME CONFERENCE, April 2017 Per Norlén, CEO
Slide 2: Disclaimer
Disclaimer This presentation regarding Alligator Bioscience AB (“Alligator”) and its contents are confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, by any medium or for any purpose. This presentation doe
Slide 3: Alligator Bioscience in brief
Alligator Bioscience in brief COMPANY HIGHLIGHTS HISTORY OF ASSET GROWTH Development of tumor-directed immuno-oncology 2016 Alligator listed on Nasdaq Stockholm antibodies to out-license after POC Fast growing market for immuno-oncology drugs with 2015 ADC-1013 entering clinical phase I and estimate
Slide 4: Financials 2016
Financials 2016 (MSEK) Actual 2016 Actual 2015 Actual 2014 Net Sales 58,2 289,8 0,0 Net Result -48,4 207,4 -76,8 R&D expenses as % of total expenses 64,3% 61,5% 54,0% Liquidity at end of year 659,1 365,6 37,4 Cash-flow from Operations -37,6 204,9 -62,7 Total cash-flow 287,1 326,2 -31,8 Equity 676,2
Slide 5: Rapid uptake of immuno-oncology
Rapid uptake of immuno-oncology Sales of existing immuno-oncology treatments Market potential for immuno-oncology Annual global cancer mortality (2012) US$ Million ~34,000 Of which melanoma <80,000 deaths Lung 1 589 800 Liver Stomach 2 623 336 Colorectum 6 389 Breast 745 517 Oesophagus 1 402 Pancrea
Slide 6: Tumor-directed immuno-oncology
Tumor-directed immuno-oncology Metastases Immune activation Tumor SYSTEMIC IMMUNO-ACTIVATION TUMOR-DIRECTED IMMUNO-ACTIVATION Systemic administration of immunotherapeutic drugs results in Selective activation of tumor-specific immune cells results in a general immune activation with risk of severe s
Slide 7: Technology platforms
Technology platforms ALLIGATOR-GOLD® FIND® ALLIGATOR-GOLD® is an antibody library comprising The FIND® technology is used to optimize the over 60 billion different antibody variants characteristics of antibodies or other proteins DIVERSITY OPTIMIZATION SUPERIOR COMPOUND Increased tumor retention
Slide 8: Solid intellectual property portfolio
Solid intellectual property portfolio More than 50 approved and/or pending patents Seven product patent families, including ADC-1013 Solid IP position for ADC-1013 with patent coverage at least until 2032 Four technology patent families, including FIND® and ALLIGATOR-GOLD® Covering all maj
Slide 9: Drug development pipeline
Drug development pipeline PRE-CLINICAL RESEARCH PHASE I PHASE II DEVELOPMENT ADC-1013* (CD40) ATOR-1015 (OX40/CTLA-4) ATOR-1016 (TNFR-SF/TAA) (TNFR-SF) (TNFR-SF/ND) TNFR-SF: Tumor Necrosis Factor Receptor-Superfamily TAA: Tumor-Associated Antigen ND: Not Disclosed *Partnered with Janssen Biotech Inc
Slide 10: ADC-1013
ADC-1013 ADC-1013 Mode of Action Immuno-modulating receptors ANTIGEN-PRESENTING CELL T CELL ANTIGEN-PRESENTING CELL T CELL PDL1 or PDL2 ? + ADC-1013 PDL1 or PDL2 PD1 – CD40 CD80 or CD86 CD28 + CD80 or CD86 CTLA4 – B7RP1 ICOS + B7-H3 ? – B7-H4 ? – T cell Dendritic HVEM BTLA – – cell KIR MHC class I o
Slide 11: ADC-1013: Key competitors
ADC-1013: Key competitors Drug Company Indications Phase Target Yervoy® (ipilimumab) Bristol-Myers Squibb Melanoma M CTLA-4 Keytruda® (pembrolizumab) Merck Melanoma, lung cancer, H&N cancer M PD-1 Approx. 70 immuno-oncology drugs are Opdivo® (nivolumab) Bristol-Myers Squibb Melanoma, lung, renal,
Slide 12: ADC-1013: Partnership with Janssen
ADC-1013: Partnership with Janssen Partnership details for ADC-1013 Description of first Phase I trial Description of agreement Royalty / Milestone potential 24 patients with Exclusive world-wide Up-front payment plus advanced solid tumors license to ADC-1013 milestones up to a total of US$695
Slide 13: ATOR-1015: Dual binding to OX40 and CTLA-4
ATOR-1015: Dual binding to OX40 and CTLA-4 Design and optimization of the CTLA-4 binding part Anti-OX40 ATOR-1015 Anti-CTLA-4 5 mutations were introduced Affinity increased 100-fold T-cell T-cell ACTIVATION OF DEPLETION OF EFFECTOR T-CELLS REGULATORY T-CELLS ATOR-1015 SUPPRESSION OF REGULATORY T-C
Slide 14: ATOR-1015: In vivo synergy
ATOR-1015: In vivo synergy OX40 and CTLA-4 surrogate (mouse) antibodies 2 500 Tumor volume (mm³) 2 000 1 500 1 000 500 0 0 5 10 15 20 25 30 Time (days) Ctr IgG (right tumor) Ctr IgG (left tumor) OX40 and CTLA4 (right tumor) OX40 and CTLA4 (left tumor) Source: Hebb and Kohrt, American Society of hema
Slide 15: ATOR-1015 promotes cell-to-cell interactions
ATOR-1015 promotes cell-to-cell interactions
Slide 16: ATOR-1015: In vitro synergy (1/2)
ATOR-1015: In vitro synergy (1/2) CTLA-4 mediated clustering of OX40 Synergistic T-cell activation ATOR-1015 Clustering No clustering Combination of monospecific αOX40 and αCTLA-4 Strong immune No/low immune 6 000 activation activation 5 000 T-eff T-eff 4 000 IL-2 (pg/ml) 3 000 CTLA-4 coated wel
Slide 17: ATOR-1015: In vitro synergy (2/2)
ATOR-1015: In vitro synergy (2/2) ATOR-1015 induces ADCC on CTLA-4/OX40 expressing cells Synergistic T-cell depletion 140 120 ADCC (fold induction) T-cell 100 80 MΦ 60 40 20 0 ATOR-1015 can induce NK or Macrophage (MФ)-mediated 0,001 0,01 0,1 1 10 100 1000 killing (ADCC) of regulatory T cells Conc
Slide 18: ATOR-1015 Positioning
ATOR-1015 Positioning Compound Originator Description Stage Positioning of ATOR-1015 Ipilimumab BMS CTLA-4 mAb L Superior safety / efficacy profile Tremelimumab AstraZeneca CTLA-4 mAb III MEDI-6469 AstraZeneca OX40 mAb II BMS-986178 BMS OX40 mAb II MOXR-0916 Roche OX40 mAb I Superior efficacy MEDI-0
Slide 19: ATOR-1016
ATOR-1016 Mode of Action Major benefits of localizing immune-activators Immune-activators inactive until reaching tumor T-cell Systemic administration T-cell ATOR-1016 Dendritic cell Tumor cell Convenient administration TUMOR Tumor directed immune ANTIGEN RELEASE activation in all tumors Poten
Slide 20: Drug development pipeline
Drug development pipeline PRE-CLINICAL RESEARCH PHASE I PHASE II DEVELOPMENT ADC-1013* (CD40) ATOR-1015 (OX40/CTLA-4) ATOR-1016 (TNFR-SF/TAA) (TNFR-SF) (TNFR-SF/ND) TNFR-SF: Tumor Necrosis Factor Receptor-Superfamily TAA: Tumor-Associated Antigen ND: Not Disclosed *Partnered with Janssen Biotech Inc
Slide 21: Strategy to maximize shareholder value
Strategy to maximize shareholder value PHASE II 1. Advance and broaden pipeline of agonistic tumor-directed immuno-oncology antibodies ADC-1013 PHASE I 2. Extend in-house product development to later- stage clinical phase prior to partnering PRE-CLINICAL ATOR-1015 DEVELOPMENT 3. Development of next
Slide 22: Thank You
“AELIGATORS a bioscience